Gomord Véronique, Sourrouille Christophe, Fitchette Anne-Catherine, Bardor Muriel, Pagny Sophie, Lerouge Patrice, Faye Loïc
CNRS UMR 6037, IFRMP 23, GDR 2590 - Université de Rouen, 76821 Mont Saint Aignan Cedex, France.
Plant Biotechnol J. 2004 Mar;2(2):83-100. doi: 10.1111/j.1467-7652.2004.00062.x.
Antibodies have long been recognized for their diagnostic and therapeutic potential. The rapidly increasing number of monoclonal antibodies approved for immunotherapy has paved the way to an even greater demand for these molecules. In order to satisfy this growing demand and to increase the production capacity, alternative systems based on antibody production in transgenic organisms are being actively explored. In this paper, we focus on transgenic plants as a promising system for the scale-up and processing of plant-made pharmaceuticals. In particular, we point out the advantages and limitations induced by glycosylation of plant-made antibodies for human therapy.
长期以来，抗体因其诊断和治疗潜力而受到认可。获批用于免疫治疗的单克隆抗体数量迅速增加，为对这些分子的更大需求铺平了道路。为了满足这种不断增长的需求并提高生产能力，基于转基因生物生产抗体的替代系统正在积极探索中。在本文中，我们重点关注转基因植物作为扩大植物源药物生产规模和进行加工的有前景的系统。特别是，我们指出了用于人类治疗的植物源抗体糖基化所带来的优势和局限性。
